Arrowhead Pharmaceuticals, Inc. (A2RR34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 20 Oct 2026
Key indicators
| Last close | BRL 36.00 |
|---|---|
| 52-week range | 25.14 – 59.95 |
| Return, 1 month / 3 months | −17.1% / −35.1% |
| Return, 1 year / 3 years | +37.6% / – |
| Trend | Below its 200-day average |
| RSI (14) | 24 |
| Volatility (1 year) | 64.7% |
| Worst drawdown (1 year) | -38.0% |
| Average daily value traded | 0.02M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Arrowhead Pharmaceuticals is a biopharmaceutical company that designs medicines using RNA interference, a technique that reduces the production of specific proteins involved in disease. Its pipeline focuses on liver and metabolic conditions, including treatments aimed at lowering harmful blood fats and addressing other disorders with few options. The company carries out its own research and development and works with partners on some programmes. It is based in Pasadena, California, in the United States.
Arrowhead Pharmaceuticals, Inc. is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code A2RR34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Arrowhead Pharmaceuticals, Inc. (A2RR34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 36.00 on 20 October 2026.
Its price-based Market X-Ray is 34 out of 100 (a weak price profile), ranking 1,149 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 37.6% and over the last three months it fell 35.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -22.4% | ||
| From 52-week high | -38.0% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -35.1% | ||
| 6-month return | -23.1% | ||
| 12-month return, skipping the last month | 66.1% | ||
| Stability (higher is calmer) | 28 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 64.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.0% | ||
| Liquidity | 42 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M BRL | ||
| Zero-volume days | 25.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | −17.1% |
| 3 months | −35.1% |
| 6 months | −23.1% |
| 1 year | +37.6% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 47.96 / 46.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.86 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.